OPKO Health (NASDAQ:OPK) Stock Price Down 3.1%

Shares of OPKO Health, Inc. (NASDAQ:OPK) dropped 3.1% during trading on Wednesday . The stock traded as low as $3.72 and last traded at $3.72. Approximately 66,438 shares traded hands during trading, a decline of 99% from the average daily volume of 6,188,090 shares. The stock had previously closed at $3.84.

Separately, LADENBURG THALM/SH SH began coverage on OPKO Health in a research report on Monday. They issued a “buy” rating and a $7.00 price objective for the company.

The company’s 50 day moving average is $3.85. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.48 and a quick ratio of 1.09. The company has a market capitalization of $2.53 billion, a price-to-earnings ratio of 19.84 and a beta of 1.77.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Wednesday, April 28th. The biotechnology company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. OPKO Health had a return on equity of 7.34% and a net margin of 6.83%. The company had revenue of $545.20 million for the quarter, compared to analysts’ expectations of $503.00 million. Equities research analysts forecast that OPKO Health, Inc. will post 0.09 EPS for the current year.

In related news, CEO Phillip Md Et Al Frost bought 200,000 shares of the stock in a transaction that occurred on Monday, June 14th. The stock was purchased at an average cost of $3.62 per share, with a total value of $724,000.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $11,109,602.62. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jon R. Cohen purchased 50,000 shares of the business’s stock in a transaction on Monday, May 10th. The shares were bought at an average price of $3.81 per share, for a total transaction of $190,500.00. Following the acquisition, the senior vice president now owns 125,000 shares in the company, valued at $476,250. The disclosure for this purchase can be found here. Insiders have acquired 775,000 shares of company stock worth $2,840,500 over the last quarter. Insiders own 41.47% of the company’s stock.

Several institutional investors have recently made changes to their positions in OPK. Baillie Gifford & Co. purchased a new stake in shares of OPKO Health during the first quarter worth approximately $31,000. Quantbot Technologies LP grew its holdings in OPKO Health by 129.9% during the 1st quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 4,122 shares in the last quarter. Matrix Asset Advisors Inc. NY purchased a new stake in shares of OPKO Health in the 4th quarter valued at approximately $40,000. Beacon Pointe Advisors LLC acquired a new stake in shares of OPKO Health in the 4th quarter valued at $40,000. Finally, Linscomb & Williams Inc. purchased a new stake in shares of OPKO Health during the 4th quarter worth $43,000. 27.79% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services.

See Also: Dow Jones Industrial Average (DJIA)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.